Outpacing US, China to gain AI supremacy by 2022, says report | Analytics Insight

“According to a recent report released by the Chinese Institute of Electronics, the AI industry of China is expected to reach US$ 20 billion by 2022. As comprehended by the White Paper on New Generation of Artificial Intelligence Industry, China’s new generation AI industry is growing steadily, and diversified applications are leading the technology into a rapid growth period.”

Read the full article @ Analytics Insight:

China – The First Artificial Intelligence Superpower | Forbes

“China is on its way to becoming the first global superpower for Artificial Intelligence.

The People’s Republic of China has the most ambitious AI strategy of all nations and provides the most resources worldwide for its implementation.

China combines a gigantic amount of data with talent, companies, research and capital to build the world’s leading AI ecosystem.”

Source: Fabian Westerheide, AI for Humans, Rise of AI (Asgard) (enlarge)

Read the full article @ Forbes:

Schweizer Unternehmen ObsEva will nach Versuchsrückschlag von Schwangerschaftsmedikament China Neustart wagen | Reuters

ObsEva hat einen Abkommen mit Chinas Yuyuan BioScience Technology geschlossen, um das Fruchtbarkeitsmedikament Nolasiban zu entwickeln und zu vermarkten.

@ Reuters | 13. Januar 2020

Switzerland’s Obseva eyes China re-start for fertility drug that failed trial | Reuters

ObsEva struck a pact with China’s Yuyuan BioScience Technology to develop and commercialize the fertility drug nolasiban, the Swiss drugmaker said on Monday as it seeks to inject new life into a medicine that had flopped a trial.

@ Reuters | January 13, 2020

Interview | “Our quiet diplomacy makes us personable” | NZZ

Felix Sutter, President of the Swiss-Chinese Chamber of Commerce, on the challenges for Swiss companies in China, the discussion about a “Lex China” and the special relationship between the Swiss and the Chinese.

@ NZZ (German) | January 7, 2020

Interview | «Unsere leise Diplomatie macht uns sympathisch» | NZZ

Felix Sutter, Präsident der Wirtschaftskammer Schweiz-China, über die Herausforderungen für Schweizer Firmen in China, die Diskussion um eine «Lex China» und das spezielle Verhältnis der Schweizer zu den Chinesen.

@ NZZ (Deutsch) | 7. Januar 2020

Even more China: Syngenta is increasingly detaching from its Swiss roots | NZZ

The owner Chem China wants to bring the agrochemical business of another Chinese state company, the Sinochem company, into the Basel group. At the same time, Syngenta receives a new CFO with experience in China.

@ NZZ | January 7, 2020

Bühler verkauft Mehlzutatengeschäft mit Sitz in China an Bakels | FoodBev Media

Bühler hat bekannt gegeben, dass das Geschäft mit Mehlzutaten für einen nicht genannten Betrag an den globalen Backzutatenkonzern Bakels verkauft wurde. Die Transaktion umfasst sämtliche Anteile an Bühler Bangsheng Food Ingredients (Guangzhou) mit Sitz in China. Damit stärkt Bakels seine Position in China.

@ FoodBev Media (Englisch) | 2. Januar 2020

Bühler sells China-based flour ingredient business to Bakels | FoodBev Media

Bühler has announced that it has sold its flour ingredient business to global bakery ingredients group Bakels for an undisclosed sum. The deal includes all shares of China-based Bühler Bangsheng Food Ingredients (Guangzhou), in a move that will strengthen Bakels’ position in China.

@ FoodBev Media (English) | January 2, 2020

Noch mehr China: Syngenta löst sich immer mehr von seinen Schweizer Wurzeln | NZZ

Der Besitzer Chem China will in den Basler Konzern das Agrochemiegeschäft eines weiteren chinesischen Staatskonzerns, der Firma Sinochem, einbringen. Zugleich erhält Syngenta einen chinaerfahrenen neuen Finanzchef.

@ NZZ | 7. Januar 2020